Weekly paclitaxel plus capecitabine versus docetaxel every 3 weeks plus capecitabine in metastatic breast cancer

Abstract

Background. We performed a randomized phase II study comparing efficacy and toxicity of weekly paclitaxel 80mg/m2 (Weetax) with three weekly docetaxel 75mg/m2 (Threetax), both in combination with oral capecitabine 1000mg/m2 twice daily for 2 weeks followed by a 1-week break. Patients. Thirty-seven women with confirmed metastatic breast cancer were randomized. Results. Median TTF was 174 (Weetax) versus 147 days (Threetax) (P=0.472). Median OS was 933 (Weetax) versus 464 days (Threetax) (P=0.191). Reasons for TTF were PD 8/18 (Weetax), 9/19 (Threetax); and toxicity: 8/18 (Weetax), 8/19 (Threetax). ORR was 72% (Weetax) versus 26% (Threetax) (P=0.01). The Threetax-combination resulted in a higher incidence of leuco-/neutropenia compared to Weetax. Grade II anemia was more pronounced in the Weetax group. No difference was found in quality of life. Conclusion. Taxanes in combination with capecitabine resulted in a high level of toxicity. Taxanes and capecitabine should be considered given sequentially and not in combination. Copyright © 2012 E. A. Wist et al.